Moderna gives first doses of COVID-19 vaccine to participants under 18 in latest trial phase

HELP OF A COMPANY HERE IN THE GRANITE STATE. IT IS CALLED VACCINE 1273. TODAY, OFFICIALS FROM A DHARNA, THE COMPANY THAT바카라 게임 웹사이트�S DEVELOPED AND TESTED THIS GROUP -- FROM MODERNA, THE COMPANY THAT바카라 게임 웹사이트�S DEVELOPED AND TESTED THIS GROUP, HAVE GAVE AN UPDATE ON THEIR EFFORTS. >> FOR THE END OF 2020, WE WILL HAVE APPROXIMATELY 20 MILLION DOSES AVAILABLE FOR THE U.S. MARKET SHOULD BE APPROVE EMERGENCY USE AUTHORIZATION BY THE END OF 2020. ANDY: MODERNA, WHICH IS BASED I MASSACHUSETTS AND WORKING TO PRODUCE THE VACCINE WITH A COMPANY IN PORTSMOUTH, CONDUCTED CLINICAL TRIALS ON 30,000 PEOPLE OF DIFFERENT AGES AND ETHNIC BACKGROUNDS, ALONG WITH PEOPLE WITH CHRONIC HEALTH CONDITIONS AND FOUND THE VACCINE WAS VERY EFFECTIVE. >> WHEN YOU ARE VACCINATED, AFTER A TWO DOSE REGIMENT, THERE WAS A 94.1% VACCINE EFFICACY. ANDY: STATE HEALTH OFFICIALS HOPE TO HAVE THE FIRST ROUND OF VACCINES PRODUCED BY PFIZER IN NEW HAMPSHIRE BY NEXT WEEK. THEY HOPE THEM A DHARNA VACCINE WILL BE HERE -- THE MODER VACCINE WILL BE HERE THE FOLLOWING WEEK. THEY FOUND SIDE EFFECTS TO BE VERY MILD, INCLUDING SORENESS AROUND THE INJECTION SITE AND HEADACHES. >> WE DID SEE A 10% LEVEL OF FATIGUE, FOR INSTANCE. MOST OF THE TOLERABILITY AND SAFETY OR ADVERSE EVENTS TYPICALLY RESULT WITHIN A SHORT PERIOD RIGHT AFTER VACCINATION WITHIN A ONE-DAY TO THREE-DAY TI PERIOD. ANDY: MODERNA OFFICIALS HOPE TO PRODUCE BETWEEN 500 MILLION

Video above: Moderna officials discuss vaccine, trials, side effects and productionModerna has announced that the first adolescent patients have been dosed in the latest phase of its COVID-19 vaccine trial. According to a news release from the company, participants ages 12 to 18 received doses in Moderna's latest phase, in which they expect to enroll 3,000 people in the same age group.Stéphane Bancel, CEO of Moderna, said the goal is to gather data that will allow for use of the company's COVID-19 vaccine ahead of the 2021 school year. 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Bancel said Moderna is encouraged by the company's vaccine trial in adults "and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population." "We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting," she said. 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Adolescent participants in this phase of Moderna's trial either receive a placebo or a dose of the vaccine during two vaccinations given 28 days apart. Moderna plans to follow up with participants until a year after the second vaccination. Moderna is the second company working on a COVID-19 vaccine to begin including younger participants in its trial.

CAMBRIDGE, Mass. —

Video above: Moderna officials discuss vaccine, trials, side effects and production

Moderna has announced that the first adolescent patients have been dosed in the latest phase of its COVID-19 vaccine trial.

According to a from the company, participants ages 12 to 18 received doses in Moderna's latest phase, in which they expect to enroll 3,000 people in the same age group.

Stéphane Bancel, CEO of Moderna, said the goal is to gather data that will allow for use of the company's COVID-19 vaccine ahead of the 2021 school year.

Bancel said Moderna is encouraged by the company's vaccine trial in adults "and this adolescent study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population."

"We hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting," she said.

Adolescent participants in this phase of Moderna's trial either receive a placebo or a dose of the vaccine during two vaccinations given 28 days apart. Moderna plans to follow up with participants until a year after the second vaccination.

Moderna is the second company working on a COVID-19 vaccine to begin including younger participants in its trial.

Moderna gives first doses of COVID-19 vaccine to participants under 18 in latest trial phase

Share

Share

Share

Top Picks